Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;83(4):e309-e311.
doi: 10.1016/j.jaad.2020.06.986. Epub 2020 Jun 27.

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms

Affiliations
Comment

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms

José Luis Galán et al. J Am Acad Dermatol. 2020 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Seltzer J.A., Okeke C.A.V., Perry J.D., Shipman W.D., Okoye G.A., Byrd A.S. Exploring the risk of severe COVID-19 infection in hidradenitis suppurativa patients. J Am Acad Dermatol. 2020;83(2):e153–e154. - PMC - PubMed
    1. Goldburg S.R., Strober B.E., Payette M.J. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058. - PubMed
    1. Blaszczak A., Trinidad J.C.L., Cartron A.M. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: safety considerations. J Am Acad Dermatol. 2020;83(1):e31. - PMC - PubMed
    1. Amerio P., Prignano F., Giuliani F., Gualdi G. COVID-19 and psoriasis: should we fear for patients treated with biologics? Dermatol Ther. 2020:e13434. doi: 10.1111/dth.13434. - DOI - PMC - PubMed
    1. Gisondi P., Facheris P., Dapavo P., et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373–374. - PMC - PubMed